Ocella: Difference between revisions
CSV import |
CSV import |
||
| Line 25: | Line 25: | ||
{{Birth control}} | {{Birth control}} | ||
{{Pharmaceutical-stub}} | {{Pharmaceutical-stub}} | ||
{{No image}} | |||
Revision as of 23:46, 10 February 2025
Ocella is a type of combined oral contraceptive pill that is used for the prevention of pregnancy. It is a generic version of the brand-name drug Yasmin, and is produced by Barr Pharmaceuticals.
Composition
Ocella contains two active ingredients: drospirenone and ethinyl estradiol. Drospirenone is a progestin, while ethinyl estradiol is a form of the hormone estrogen. These two hormones work together to prevent ovulation, alter the cervical mucus to make it more difficult for sperm to reach the egg, and change the lining of the uterus to prevent implantation of a fertilized egg.
Usage
Ocella is taken orally, once a day, at the same time each day. Each pack of Ocella contains 28 pills: 21 active pills and 7 inactive (or placebo) pills. The inactive pills are included to help the user remember to take a pill every day and to mimic the natural menstrual cycle.
Side Effects
Like all medications, Ocella can cause side effects. Common side effects include nausea, vomiting, headache, bloating, breast tenderness, and changes in weight or appetite. More serious side effects can include blood clots, stroke, and heart attack. Women who smoke, are over 35, or have certain health conditions are at a higher risk for these serious side effects.
Interactions
Ocella can interact with other medications, which can decrease its effectiveness or increase the risk of side effects. Some of these medications include rifampin, griseofulvin, phenytoin, and St. John's wort. It is important to tell your healthcare provider about all the medications you are taking before starting Ocella.
See Also
| Birth control and family planning | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This birth control related article is a stub.
|
This pharmaceutical related article is a stub. You can help WikiMD by expanding it.